- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01942382
A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
10 september 2013 uppdaterad av: Janssen Pharmaceutical K.K.
Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Subjects With Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics (study of what the body does to a drug) and safety of paliperidone palmitate ranging from 75 to 150 milligram equivalents in repeated doses (4 injections) administered in the deltoid muscle (muscle in the shoulder) or gluteal muscle (group of muscles present in the buttocks) in participants with schizophrenia.
Studieöversikt
Detaljerad beskrivning
This is a multicenter (study conducted at multiple sites), open label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), parallel-group (each group of participants will be treated at the same time) study.
Approximately, 60 participants will be enrolled in the study.
This study will consist of a screening phase (maximum 14 days), an observation phase (92 days), and a follow-up phase (98 days).
Participants will be randomly assigned to treatment group A, B, or C.
During the observation phase, participants will receive injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in the deltoid muscle or gluteal muscle as applicable on Days 1, 8, 36, and 64 alternating between sides (left/right).
Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, physical examination, injection site reaction, drug-induced extrapyramidal symptoms scale, and visual analog scale which will be evaluated throughout the study.
The total study duration for each participant will be approximately 190 days.
Studietyp
Interventionell
Inskrivning (Faktisk)
76
Fas
- Fas 1
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
20 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:- Participants had to have the capability to provide informed consent in writing to participate in the study
- Participants with a diagnosis of schizophrenia in accordance with the diagnostic criteria for Diagnostic and Statistical Manual of Mental Disorders -IV-TR (DSM-IV-TR)
- Participants whose psychiatric symptom is considered stable by the investigator/subinvestigator at the time of giving informed consent
- Participants with a Positive and Negative Syndrome Scale (PANSS) score of less than or equal to 4 (moderate) in the following 9 items at screening: delusion, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility, uncooperativeness, poor impulse control
- Participants with an experience of taking a risperidone formulation or a paliperidone formulation by 8 days before the initial day (Day 1) of the study treatment
Exclusion Criteria:- DSM-IV-TR diagnosis other than schizophrenia
- DSM-IV-TR diagnosis of substance-related disorders within 180 days before the date of screening
- At a risk of suicide or other-injurious behavior as considered by the investigator/subinvestigator , and participants with a history of suicide attempts
- Concurrent condition of Parkinson's disease (except for drug-induced extrapyramidal syndrome) - Concurrent condition or history of symptomatic cerebrovascular accident
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment A
Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
|
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Andra namn:
|
|
Experimentell: Treatment B
Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
|
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Andra namn:
|
|
Experimentell: Treatment C
Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
|
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Plasma concentration of unchanged drug (Paliperidone palmitate)
Tidsram: Days 1 to 190
|
Days 1 to 190
|
|
|
Plasma concentration of active metabolite (paliperidone)
Tidsram: Days 1 to 190
|
Days 1 to 190
|
|
|
Plasma concentration of enantiomer of paliperidone palmitate (R078543)
Tidsram: Days 1 to 190
|
Days 1 to 190
|
|
|
Plasma concentration of enantiomer paliperidone palmitate (R078544)
Tidsram: Days 1 to 190
|
Days 1 to 190
|
|
|
Maximum Observed Plasma Concentration (Cmax) of paliperidone palmitate
Tidsram: Days 1 to 190
|
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
|
Days 1 to 190
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of paliperidone palmitate
Tidsram: Days 1 to 190
|
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Days 1 to 190
|
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of paliperidone palmitate
Tidsram: Days 1 to 190
|
The Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) is a measure of the plasma paliperidone concentration from time zero to end of dosing interval.
It is used to characterize drug absorption.
|
Days 1 to 190
|
|
Number of participants with adverse events
Tidsram: Up to Day 190
|
Up to Day 190
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
Tidsram: Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
The PANSS is a medical scale that assesses various symptoms of schizophrenia.
The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology).
The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
Higher scores indicate worsening.
|
Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
|
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score
Tidsram: Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.
A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants".
Higher scores indicate worsening.
|
Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 april 2009
Primärt slutförande (Faktisk)
1 mars 2010
Avslutad studie (Faktisk)
1 mars 2010
Studieregistreringsdatum
Först inskickad
10 september 2013
Först inskickad som uppfyllde QC-kriterierna
10 september 2013
Första postat (Uppskatta)
16 september 2013
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
16 september 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 september 2013
Senast verifierad
1 september 2013
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Schizofrenispektrum och andra psykotiska störningar
- Schizofreni
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Depressiva medel i centrala nervsystemet
- Antipsykotiska medel
- Lugnande medel
- Psykotropa droger
- Serotoninmedel
- Dopaminmedel
- Serotonin 5-HT2-receptorantagonister
- Serotoninantagonister
- Dopamin D2-receptorantagonister
- Dopaminantagonister
- Paliperidonpalmitat
Andra studie-ID-nummer
- CR100413
- PALM-JPN-3 (Annan identifierare: Janssen Pharmaceutical K.K., Japan)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .